Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease

Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other... Clin Res Cardiol (2018) 107:201–213 DOI 10.1007/s00392-017-1172-4 ORIGINAL PAPER Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease 1 1 2 1 Insa E. Emrich  · Adam M. Zawada  · Jens Martens-Lobenhoffer  · Danilo Fliser  · 3 1 2 Stefan Wagenpfeil  · Gunnar H. Heine  · Stefanie M. Bode-Böger   Received: 24 August 2017 / Accepted: 20 October 2017 / Published online: 3 November 2017 © Springer-Verlag GmbH Germany 2017 Abstract annually for CKD progression and for incident atheroscle- Background Chronic kidney disease (CKD) is associated rotic cardiovascular events. with increased risk of renal and cardiovascular events. It has Results During 5.1 ± 2.1 years follow-up, 80 patients dis- been claimed that endogenous methylarginines, asymmetric played CKD progression and 145 patients developed inci- dimethylarginine (ADMA) and symmetric dimethylarginine dent atherosclerotic cardiovascular events. In univariate (SDMA), are contributing factors. However, earlier studies Cox regression analyses, elevated plasma levels of all five were partly contradictory and mainly focused on prevalent metabolites were associated with both CKD progression and dialysis patients. Moreover, the potential contribution of atherosclerotic cardiovascular disease. However, adjustment degradation products, such as acetylated ADMA and SDMA for confounders attenuated the prognostic implications of (AcADMA and AcSDMA) and other methylarginines ADMA, LNMMA, AcADMA and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Zeitschrift für Kardiologie Springer Journals

Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease

Loading next page...
 
/lp/springer_journal/symmetric-dimethylarginine-sdma-outperforms-asymmetric-JzCs6wkAGY
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by Springer-Verlag GmbH Germany
Subject
Medicine & Public Health; Cardiology
ISSN
0300-5860
eISSN
1861-0692
D.O.I.
10.1007/s00392-017-1172-4
Publisher site
See Article on Publisher Site

Abstract

Clin Res Cardiol (2018) 107:201–213 DOI 10.1007/s00392-017-1172-4 ORIGINAL PAPER Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease 1 1 2 1 Insa E. Emrich  · Adam M. Zawada  · Jens Martens-Lobenhoffer  · Danilo Fliser  · 3 1 2 Stefan Wagenpfeil  · Gunnar H. Heine  · Stefanie M. Bode-Böger   Received: 24 August 2017 / Accepted: 20 October 2017 / Published online: 3 November 2017 © Springer-Verlag GmbH Germany 2017 Abstract annually for CKD progression and for incident atheroscle- Background Chronic kidney disease (CKD) is associated rotic cardiovascular events. with increased risk of renal and cardiovascular events. It has Results During 5.1 ± 2.1 years follow-up, 80 patients dis- been claimed that endogenous methylarginines, asymmetric played CKD progression and 145 patients developed inci- dimethylarginine (ADMA) and symmetric dimethylarginine dent atherosclerotic cardiovascular events. In univariate (SDMA), are contributing factors. However, earlier studies Cox regression analyses, elevated plasma levels of all five were partly contradictory and mainly focused on prevalent metabolites were associated with both CKD progression and dialysis patients. Moreover, the potential contribution of atherosclerotic cardiovascular disease. However, adjustment degradation products, such as acetylated ADMA and SDMA for confounders attenuated the prognostic implications of (AcADMA and AcSDMA) and other methylarginines ADMA, LNMMA, AcADMA and

Journal

Zeitschrift für KardiologieSpringer Journals

Published: Nov 3, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off